Notably, our results further uncovered the oncogenic activities of IL‐2 in prostate cancer cells, wherein IL‐2 was subjected to TRIM66‐positive regulation, and IL‐2 silencing greatly compromised cell proliferation, invasion and migration. Here, TRIM66 is linked to prostate carcinoma.